<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316717</url>
  </required_header>
  <id_info>
    <org_study_id>IMM-124E-2001</org_study_id>
    <nct_id>NCT02316717</nct_id>
  </id_info>
  <brief_title>A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis</brief_title>
  <official_title>A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immuron Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immuron Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and preliminary efficacy of two dose levels of IMM-124E
      in reducing liver fat and/or serum alanine aminotransaminase (ALT) compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who provide voluntary written informed consent will be screened for eligibility.
      Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to
      participate.

      Eligible subjects will be randomized at the Baseline visit to receive one of the three study
      treatments three times daily for a period of 24 weeks. Each subject will return to the study
      clinic for assessment and required study procedures on Day 7, 14 and 28 and every 4 weeks
      thereafter until Week 24.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Changes in body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Fat Content of the Liver</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Mean change from Baseline in Percentage Fat Content of the Liver measured by Magnetic Resonance Imaging (MRI) at Week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Respiratory Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse Rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Pulse Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Systolic Blood Pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Diastolic Blood Pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology, Coagulation, Clinical Chemistry, Serum Lipids, Blood Glucose and Urinalysis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Clinical Laboratory tests (Hematology, Coagulation, Clinical Chemistry, Serum Lipids, Blood Glucose and Urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Alanine Aminotransaminase (ALT)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean change from Baseline in Serum Alanine Aminotransaminase (ALT) at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak serum concentration (Cmax)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Peak serum concentration (Cmax) of IMM-124E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum concentration (Cmin)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Minimum serum concentration (Cmin) of IMM-124E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve (AUC)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Area Under the Concentration Time Curve (AUC) of IMM-124E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life (T1/2)</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Elimination Half Life (T1/2) of IMM-124E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Body Mass Index (BMI) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Waist Circumference at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist:Hip Ratio</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Waist:Hip Ratio at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (HB)A1C</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Hemoglobin(HB)A1C at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Total Cholesterol at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Triglycerides at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein (LDL)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of Low Density Lipoprotein (LDL) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (HDL)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from Baseline of High Density Lipoprotein (HDL) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Alanine Aminotransaminase (ALT)</measure>
    <time_frame>0, 4, 8, 12, 16, 20 and 24 Weeks</time_frame>
    <description>Mean change from Baseline of serum ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Aspartate Aminotransaminase (AST)</measure>
    <time_frame>0, 4, 8, 12, 16, 20 and 24 Weeks</time_frame>
    <description>Mean change from Baseline of Serum AST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>0, 4, 8, 12, 16, 20 and 24 Weeks</time_frame>
    <description>Mean change from Baseline of Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>0, 4, 8, 12, 16, 20 and 24 Weeks</time_frame>
    <description>Mean change from Baseline of Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma Glutamyl Transpeptidase (GGT)</measure>
    <time_frame>0, 4, 8, 12, 16, 20 and 24 Weeks</time_frame>
    <description>Mean change from Baseline of Gamma Glutamyl Transpeptidase (GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Alanine Aminotransaminase (ALT)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Number of patients with ALT within the normal reference range at Week 24(defined a &lt;19 IU/L for women and &lt;30 IU/L for men)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory Cytokines and other markers</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Serum Concentrations of Lipopolysaccharide (LPS), C-Reactive Protein (CRP), CK-18 fragments, C-peptide, Adiponectin and Cytokines IL6, IL12, IFN gamma and TNF alpha</description>
  </other_outcome>
  <other_outcome>
    <measure>Regulatory T cells in Peripheral Blood Mononuclear Cells</measure>
    <time_frame>0, 12 and 24 Weeks</time_frame>
    <description>Relative levels of Regulatory T cells in Peripheral Blood Mononuclear Cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut Microbiome from Fecal Samples</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Characterization of the gut microbiome from fecal samples by DNA extraction and Bacterial ribosomal DNA amplification and sequencing</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal LPS levels</measure>
    <time_frame>0, 4, 12 and 24 Weeks</time_frame>
    <description>Gastrointestinal LPS levels from fecal samples</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Non-alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM-124E, 600 mg three times daily, orally plus matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM-124E, 1200 mg three times daily, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, three times daily, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMM-124E</intervention_name>
    <description>IMM-124E</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Treatment Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Provision of written informed consent.

          3. Diagnosis of NASH, histologically proven within 12 months of Screening with

               -  NASH activity score (NAS) of 4 or more

               -  cytologic ballooning score of at least 1;

               -  10% or more macrovescicular steatosis.

               -  Hematoxylin &amp; Eosin (H&amp;E) stained slides and/or paraffin block available for
                  independent assessment.

          4. HBA1C of &lt;9.0

          5. Agree to the use of effective contraceptive measures if either male or female of child
             bearing potential.

        Exclusion Criteria:

          1. Presence of vascular liver disease or cirrhosis;

          2. Presence of liver disease with other cause (autoimmune, metabolic, medication
             induced);

          3. BMI &lt;25 kg/m^2;

          4. Alcohol use &gt;30 g/day;

          5. Type 1 diabetes;

          6. 6. History of major bariatric surgery (not including balloon / sleeve gastrectomy);

          7. Weight loss or gain of 5kg or more in the past 6 months or &gt;10% change in bodyweight
             in the past 12 months;

          8. Contraindication for MRI;

          9. Inadequate venous access;

         10. Lactating/breastfeeding/pregnant at Screening or Baseline;

         11. HIV antibody positive, hepatitis B surface antigen positive (HBsAg) or Hepatitis C
             virus (HCV)-RNA positive;

         12. Receiving an elemental diet or parenteral nutrition;

         13. Concurrent conditions

               -  Inflammatory bowel disease;

               -  Unstable angina, myocardial infarction, transient ischemic events, or stroke
                  within 24 weeks of Screening;

               -  Ongoing infectious, ongoing multi-systemic immune-mediated and/or concurrent or
                  past malignant disease;

               -  Any other concurrent condition which, in the opinion of the investigator, could
                  impact adversely on the subject participating or on the interpretation of the
                  study data;

         14. Concurrent medications including:

               -  anti-NASH therapy(s) taken for more than 10 continuous days in the last 3 months.
                  These include S-adenosyl methionine (SAM-e), betaine, milk thistle, probiotic
                  supplements (other than yoghurt), vitamin E and gemfibrozil.

                    -  NB: If vitamin E or gemfibrozil are used, the dose must be stable and liver
                       biopsy confirming diagnosis of NASH subsequent to commencing treatment;
                       commencing treatment;

                    -  Wash out for any of the anti-NASH therapies is as follows: under 10 days no
                       washout required, more than 10 days and up to 3 months treatment requires 6
                       weeks washout. Any treatment of over 3 months would require to re-biopsy to
                       ensure histological eligibility

               -  thiazolidinediones (glitazones), dipeptidyl peptidase 4 inhibitors (gliptins) or
                  glucagon-like peptide-1 analogs in the last 6 months. If treatment commenced and
                  is stable for more than 6 month prior to the determinant biopsy and the dose is
                  still stable at time of study entry, subjects will be eligible for recruitment.

               -  Allowable anti-diabetic treatment includes metformin and/or sulfonylureas
                  administered at constant dose for at least 2 months prior to study entry.

               -  Subjects treated with Insulin are eligible if clinically stable on insulin
                  treatment (i.e. no recurrent acute hypo-/hyperglycemic episodes diagnosed
                  clinically and by Glucose serum levels of &lt;50 mg/dL and &gt;200 mg/dL respectively)
                  for at least 2 months prior to study entry.

               -  immune modulatory agents including

                    -  In the last 3 months:

                    -  systemic steroids for more than 7 days.

                    -  daily treatment with multiple non-steroidal anti-inflammatory drugs (such as
                       aspirin &gt;100mg/day, ibuprofen, naproxen, meloxicam, celecoxib) for more than
                       1 month within 3 months prior to study entry;

                    -  In the last 12 months:

                    -  azathioprine, 6-mercaptopurine, methotrexate, cyclosporin, anti-TNFα
                       therapies (infliximab, adalimumab, etanercept) or anti-integrin therapies
                       (namixilab) ;

               -  more than 10 consecutive days oral or parenteral antibiotics within 4 weeks prior
                  to study entry (Note: such subjects would not be included in the stool and PBMC
                  analysis).

               -  variable dose of antilipidemic agents (3-hydroxy-3-methyl-glutaryl (HMG)-Co-A
                  reductase inhibitors - &quot;statins&quot;) in the 3 months prior to study entry.

         15. The following laboratory abnormalities:

               -  Neutrophil count ≤1.0 x 10^9/L

               -  Platelets &lt;100 x 10^9/L

               -  Hemoglobin &lt;10 g/dL

               -  Albumin &lt;3.5 g/dL

               -  International Normalized Ratio (INR) &gt;1.5

               -  Total bilirubin &gt;1.5 x upper limit of reference range (unless Gilbert's syndrome
                  or extrahepatic source as denoted by increased indirect bilirubin fraction)

               -  Either creatinine clearance ≤60 mL/minute calculated by Cockroft Gault or
                  creatinine &gt;1.5x upper limit of reference range.

         16. Known substance abuse, including inhaled or injected drugs in the year prior to
             Screening.

         17. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to
             study products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Peres</last_name>
    <role>Study Director</role>
    <affiliation>Immuron Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Hepatology Research at CTRB</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Liver Centre</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor St Lukes Medical Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Centre</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Immaculate Hospital</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours St Marys Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Centre</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Nepean Hospital</name>
      <address>
        <city>Penrith</city>
        <state>New South Wales</state>
        <zip>2750</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Centre</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center (Ichilov)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>November 19, 2017</last_update_submitted>
  <last_update_submitted_qc>November 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

